Zacks Research Brokers Reduce Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – Investment analysts at Zacks Research dropped their Q3 2025 earnings estimates for shares of West Pharmaceutical Services in a report released on Wednesday, April 9th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will earn $1.64 per share for the quarter, down from their prior forecast of $1.65. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ FY2025 earnings at $6.18 EPS, Q1 2026 earnings at $1.40 EPS, Q2 2026 earnings at $1.78 EPS, Q3 2026 earnings at $1.91 EPS, Q4 2026 earnings at $2.00 EPS, FY2026 earnings at $7.09 EPS, Q1 2027 earnings at $1.56 EPS and FY2027 earnings at $8.17 EPS.

A number of other research analysts have also commented on the company. Deutsche Bank Aktiengesellschaft raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a report on Friday, February 14th. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, February 27th. Evercore ISI initiated coverage on shares of West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 price objective for the company. KeyCorp decreased their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Citigroup initiated coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $332.50.

West Pharmaceutical Services Price Performance

NYSE WST opened at $210.75 on Friday. West Pharmaceutical Services has a fifty-two week low of $187.43 and a fifty-two week high of $394.42. The stock’s 50-day moving average is $231.81 and its two-hundred day moving average is $289.85. The firm has a market cap of $15.24 billion, a P/E ratio of 31.50, a price-to-earnings-growth ratio of 6.74 and a beta of 1.22. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The company had revenue of $748.80 million for the quarter, compared to analyst estimates of $739.59 million.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio is currently 12.56%.

Institutional Trading of West Pharmaceutical Services

Institutional investors and hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP raised its stake in shares of West Pharmaceutical Services by 69.4% in the 3rd quarter. Quantinno Capital Management LP now owns 3,838 shares of the medical instruments supplier’s stock valued at $1,152,000 after buying an additional 1,573 shares in the last quarter. Wellington Management Group LLP raised its position in West Pharmaceutical Services by 13.9% in the third quarter. Wellington Management Group LLP now owns 6,557 shares of the medical instruments supplier’s stock worth $1,968,000 after purchasing an additional 799 shares in the last quarter. MML Investors Services LLC lifted its stake in West Pharmaceutical Services by 2.4% during the third quarter. MML Investors Services LLC now owns 18,517 shares of the medical instruments supplier’s stock worth $5,558,000 after purchasing an additional 437 shares during the period. Geode Capital Management LLC boosted its holdings in West Pharmaceutical Services by 0.7% during the third quarter. Geode Capital Management LLC now owns 1,740,183 shares of the medical instruments supplier’s stock valued at $520,569,000 after purchasing an additional 12,850 shares in the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of West Pharmaceutical Services by 0.9% in the 3rd quarter. Toronto Dominion Bank now owns 36,245 shares of the medical instruments supplier’s stock valued at $10,879,000 after purchasing an additional 334 shares during the period. 93.90% of the stock is currently owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.